Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of a 1% Topical Formulation of KM-001 for the Treatment of Type I Punctate Palmoplantar Keratoderma or Pachyonychia Congenita

NCT05956314 is registered in ClinicalTrials.gov with Orvida Pharma (formerly Kamari Pharma) as lead sponsor.

NCT NCT05956314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05956314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b, Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of a 1% Topical Formulation of KM-001 for the Treatment of Type I Punctate Palmoplantar Keratoderma or Pachyonychia Congenita
Lead sponsor
Orvida Pharma (formerly Kamari Pharma)
Phase
Phase 1
Overall status
Completed
Start date
March 6, 2023
Completion date
November 7, 2024
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pachyonychia congenita, punctate palmoplantar keratoderma type 1